Suspension of trading

NeuBase Therapeutics, Inc. Stock

O7P

US64132K2015

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG Other stock markets 02:03:16 2024-05-13 EDT			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.12M 1.03M 947K 1.8M 123M 1.83M 12.3M 4.83M 60.1M 4.8M 4.69M 207M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.12M 1.03M 947K 1.8M 123M 1.83M 12.3M 4.83M 60.1M 4.8M 4.69M 207M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news : NeuBase Therapeutics, Inc.

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
24-06-27	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
24-05-28	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	2021-10-31

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	2025-01-03

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-79.00%	1.39M
LONZA GROUP AG	-0.17%	+1.47%	+3.16%	+7.43%	50.35B
REVOLUTION MEDICINES, INC.	-0.29%	-2.81%	+387.81%	+593.12%	39.32B
IQVIA HOLDINGS INC.	-0.49%	+1.48%	+31.16%	-6.58%	34.69B
BEONE MEDICINES AG	+1.53%	+3.11%	+15.41%	+57.28%	34.08B
CELLTRION, INC.	+1.68%	-1.40%	+4.23%	+27.34%	26.63B
ASCENDIS PHARMA A/S	+1.13%	-3.11%	-	-	16.49B
MEDPACE HOLDINGS, INC.	-1.29%	-0.52%	+69.24%	+113.95%	15.31B
EUROFINS SCIENTIFIC SE	+0.43%	+0.55%	+15.19%	+17.46%	13.8B
ICON PUBLIC LIMITED COMPANY	+2.45%	+3.99%	+18.20%	-29.77%	12.87B
Average	+0.50%	-0.78%	+60.49%	+77.91%	24.35B
Weighted average by Cap.	+0.49%	-0.32%	+82.06%	+122.23%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company